Karin Blumer, director of global patient engagement at Swiss giant Novartis, gives fascinating insights into the global patient advocacy landscape today and how Novartis interacts with it, the work being done on patient engagement and expectation management for the firm's cutting-edge CAR-T therapies, and how a stronger patient voice can converge with scientific development within Big Pharma companies.
It must be remembered that patient empowerment is good for all of us, because all of us could be patients – or caregivers – one day. We know that an empowered patient who really understands what is happening to them will better comply with their treatment
